176 related articles for article (PubMed ID: 38571483)
21. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
22. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
23. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
[TBL] [Abstract][Full Text] [Related]
24. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics.
Fan Z; Yu H; Cui N; Kong X; Liu X; Chang Y; Wu Y; Sun L; Wang G
Exp Cell Res; 2015 Jul; 335(1):68-81. PubMed ID: 25936772
[TBL] [Abstract][Full Text] [Related]
25. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro.
He XR; Wu XP
Chin Med Sci J; 2008 Mar; 23(1):54-9. PubMed ID: 18437912
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis.
Kim JH; Liu L; Lee SO; Kim YT; You KR; Kim DG
Cancer Res; 2005 Jul; 65(14):6312-20. PubMed ID: 16024633
[TBL] [Abstract][Full Text] [Related]
27. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
28. A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.
Kitchen P; Lee KY; Clark D; Lau N; Lertsuwan J; Sawasdichai A; Satayavivad J; Oltean S; Afford S; Gaston K; Jayaraman PS
Cancer Res; 2020 Feb; 80(4):757-770. PubMed ID: 31843982
[TBL] [Abstract][Full Text] [Related]
29. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
[TBL] [Abstract][Full Text] [Related]
30. Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis.
Takayama Y; Kokuryo T; Yokoyama Y; Ito S; Nagino M; Hamaguchi M; Senga T
Cancer Lett; 2010 Oct; 296(1):27-34. PubMed ID: 20381954
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.
Hou YJ; Dong LW; Tan YX; Yang GZ; Pan YF; Li Z; Tang L; Wang M; Wang Q; Wang HY
Lab Invest; 2011 Aug; 91(8):1146-57. PubMed ID: 21647092
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis.
Chang YC; Li CH; Chan MH; Chen MH; Yeh CN; Hsiao M
Cell Death Dis; 2022 Apr; 13(4):391. PubMed ID: 35449153
[TBL] [Abstract][Full Text] [Related]
33. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1.
Wang TH; Wan JY; Gong X; Li HZ; Cheng Y
Oncol Rep; 2012 Nov; 28(5):1681-6. PubMed ID: 22941407
[TBL] [Abstract][Full Text] [Related]
34. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
35. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
[TBL] [Abstract][Full Text] [Related]
36. Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells.
Junking M; Rattanaburee T; Panya A; Budunova I; Haegeman G; Yenchitsomanus PT
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2673-2681. PubMed ID: 32986368
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
38. Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Račkauskas R; Zhou D; Ūselis S; Strupas K; Herr I; Schemmer P
Oncol Rep; 2017 Jun; 37(6):3660-3666. PubMed ID: 28498473
[TBL] [Abstract][Full Text] [Related]
39. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
